Reactive oxygen species in cancer: Current findings and future directions

Cancer Science - Tập 112 Số 10 - Trang 3945-3952 - 2021
Hajime Nakamura1, Kohichi Takada1
1Department of Medical Oncology, Sapporo Medical University School of Medicine, Sapporo, Japan

Tóm tắt

Abstract

Reactive oxygen species (ROS), a class of highly bioactive molecules, have been widely studied in various types of cancers. ROS are considered to be normal byproducts of numerous cellular processes. Typically, cancer cells exhibit higher basal levels of ROS compared with normal cells as a result of an imbalance between oxidants and antioxidants. ROS have a dual role in cell metabolism: At low to moderate levels, ROS act as signal transducers to activate cell proliferation, migration, invasion, and angiogenesis. In contrast, high levels of ROS cause damage to proteins, nucleic acids, lipids, membranes, and organelles, leading to cell death. Extensive studies have revealed that anticancer therapies that manipulate ROS levels, including immunotherapies, show promising in vitro as well as in vivo results. In this review, we summarize molecular mechanisms and oncogenic functions that modulate ROS levels and are useful for the development of cancer therapeutic strategies. This review also provides insights into the future development of effective agents that regulate the redox system for cancer treatment.

Từ khóa


Tài liệu tham khảo

Sung H, 2021, Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J Clin, 10, 1

10.1016/j.molcel.2012.09.025

10.1038/nrc2981

10.1186/s13046-018-0909-x

10.1016/j.molmed.2017.03.004

10.1042/bj3130017

10.1016/j.phrs.2015.06.013

10.1038/nrd4002

10.18632/oncotarget.11830

10.1126/scitranslmed.3007653

10.1038/nature15726

10.1038/s12276-020-0384-2

10.1038/nature08268

10.1016/S0304-3835(98)00306-1

10.1002/ijc.22088

10.1073/pnas.0800076105

10.18632/oncotarget.19508

10.1038/s41417-018-0056-8

10.1016/j.freeradbiomed.2017.01.004

10.1196/annals.1427.015

10.1186/1756-8722-6-19

10.1074/jbc.M106474200

10.1016/j.cell.2005.02.001

10.1007/s00204-008-0313-y

10.1089/ars.2012.5014

10.1152/physrev.00040.2012

10.1152/ajplung.90461.2008

10.1080/09553009414550041

10.1016/j.molmed.2004.09.003

10.1038/nrc3278

10.1016/j.redox.2012.10.001

10.1146/annurev-pharmtox-011112-140320

10.1016/j.canlet.2008.03.036

10.1038/349431a0

10.1111/j.1349-7006.2011.01869.x

10.1038/nchembio.1416

10.1016/j.abb.2015.11.025

Kato J, 2001, Normalization of elevated hepatic 8‐hydroxy‐2'‐deoxyguanosine levels in chronic hepatitis C patients by phlebotomy and low iron diet, Cancer Res, 61, 8697

10.1007/s00535-007-2095-z

10.1038/s41598-021-83138-8

10.1016/j.freeradbiomed.2012.06.006

10.7326/M19-0916

10.1007/s10238-019-00592-5

10.1016/j.bbamcr.2016.09.012

10.1023/A:1009616228304

10.1038/nrm2434

10.1038/cdd.2014.150

10.3390/ijms19113466

10.1007/s10571-015-0166-x

10.1038/ja.2017.104

10.1038/sj.emboj.7601623

10.1016/j.redox.2014.12.003

10.1016/j.freeradbiomed.2009.02.019

10.1177/1534735404270335

10.1371/journal.pone.0081162

10.1038/nrd1984

10.1038/s41467-018-02915-8

10.1038/sj.onc.1206948

10.1016/j.biopha.2017.10.129

10.1016/j.biopha.2018.05.062

10.1038/nm1093

10.1038/ni1178

10.3390/cancers11081191

10.1016/j.cell.2015.05.025

10.1038/ni.3868

10.1038/s41467-020-18745-6

10.1016/j.immuni.2013.08.004

10.1073/pnas.1620433114

10.1016/j.molcel.2020.12.024

10.4049/jimmunol.180.5.3072